C4 Therapeutics, Inc. (CCCC) - Q2 2025 10-Q Summary
Business Context and Reporting Period
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) medicines using its proprietary TORPEDO platform. The company focuses on oncology indications, with its most advanced candidate, cemsidomide, in Phase 1/2 trials for multiple myeloma and non-Hodgkin lymphoma. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $6.5 million | $12.0 million | $13.7 million | $15.0 million |
| Net Loss | $(26.0) million | $(17.7) million | $(52.3) million | $(46.1) million |
| Loss Per Share (Basic/Diluted) | $(0.37) | $(0.26) | $(0.74) | $(0.67) |
| Operating Expenses | $35.0 million | $33.4 million | $71.4 million | $68.7 million |
| Cash & Marketable Securities | $223.0 million (as of June 30, 2025) | |||
| Accumulated Deficit |
Note: Revenue is derived entirely from collaboration agreements (Roche, Merck, MKDG, Betta Pharma, Biogen). The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 46% in Q2 2025 compared to Q2 2024. This was primarily driven by an $8.0 million decrease in revenue from the Biogen collaboration, where a milestone was recognized in full in Q2 2024. This decline was partially offset by increased revenue from the MKDG and Roche agreements.
- Increased Operating Loss: Net loss widened by $8.3 million in Q2 2025 compared to the prior year quarter, driven by higher R&D expenses and lower revenue.
- R&D Expenses: R&D expenses increased by $2.4 million in Q2 2025 (to $26.2 million) due to ongoing clinical trials for cemsidomide and increased preclinical activities.
- Restructuring: No restructuring expenses were incurred in 2025, compared to $2.4 million in the first half of 2024.
Guidance, Outlook, and Risks
- Liquidity: Management expects cash, cash equivalents, and marketable securities of $223.0 million to fund operations for at least the next 12 months (through mid-2027 based on prior guidance context, though the filing explicitly states "at least the next twelve months").
- Product Pipeline:
- Cemsidomide: Prioritized for Multiple Myeloma (MM) development; Phase 1/2 data showed compelling activity.
- CFT1946: The company decided not to advance this BRAF V600 mutant degrader beyond the current Phase 1 trial.
- CFT8919: Phase 1 trial initiated by partner Betta Pharma in Greater China is ongoing.
- Collaboration Milestones: In Q2 2025, the company achieved a $2.0 million milestone for each of two active targets under the Roche agreement and a $1.0 million discovery milestone under the MKDG agreement.
- Risks: Key risks include the need for substantial additional capital to fund future operations, the unproven nature of the TORPEDO platform, potential clinical trial failures, and reliance on third-party manufacturers and collaborators.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for capital depletion given the $52.3 million net loss in the first half of 2025 and the decision to halt CFT1946 development.
- Revenue Recognition: Review the specific terms of the Betta Pharma and Roche agreements to understand the timing of future milestone payments and the $161.4 million in unsatisfied performance obligations.
- Collaboration Status: Confirm the status of the Biogen agreement, which contributed significantly to 2024 revenue but showed zero revenue in 2025.
- Capital Markets: Note that the 2021 At-The-Market (ATM) program expired in November 2024, and no sales were made under the new 2024 ATM program in the first half of 2025.
- Regulatory Environment: Monitor the impact of the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 on orphan drug exemptions and Medicaid spending, as noted in the risk factors.